Physostigmine: Difference between revisions
(Add MedicationDose SMW query table for dynamic indications by condition) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| Line 50: | Line 50: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
|mainlabel=- | |mainlabel=- | ||
Latest revision as of 21:57, 20 March 2026
General
- Type: acetylcholinesterase inhibitor
- Dosage Forms: IV/IM
- Common Trade Names: Antilirium
- As opposed to pyridostigmine, physostigmine does cross the blood brain barrier
Adult Dosing
Anticholinergic toxicity
- 0.5-2 mg IV over 5 min
Non-depolarizing neuromuscular blockade reversal
- 0.5-1 mg IM/IV q10 min prn
Pediatric Dosing
- 0.02 mg/kg repeat every 5-10 minutes until adequate response, max of 2 mg
- No faster than 0.5 mg/min
Special Populations
- Pregnancy Rating: C
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- TCA toxicity
- Can cause asystole
Adverse Reactions
- Side effects: bradycardia, dysrhythmias, cholinergic excess
- Always have atropine at the bedside for bradycardia or cholinergic excess
Pharmacology
- Reversible AChE inhibitor, that increases concentration of acetylcholine
- Indirectly stimulates both nicotinic and muscarinic ACh receptors
- Metabolism via CYP450
- Excretion minimally via urine
- Onset of action: 15-20min
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Jimson weed | 0.5-2mg IV at rate no more than 1mg/min | Severe anticholinergic toxicity | IV | Adult |
| Jimson weed | 0.02mg/kg IV at rate no more than 0.5mg/min | Severe anticholinergic toxicity | IV | Pediatric |
